BIO vs CIMO
BIO (BIO) versus Chimera Investment Corporation (CIMO) — a side-by-side from cached financials, not a winner call.
BIO (BIO) common stock.
Chimera Investment Corporation (CIMO) common stock listed on US.
Latest reported BIO revenue for 2025-12-31 was $2.58B. Net income was $759.9M. Revenue was up 0.7% from 2024-12-31 to 2025-12-31. BIO currently screens at market cap $0.
CIMO does not have a complete income-statement cache yet.
BIO currently screens at market cap $0. CIMO currently screens at market cap $0.
Not investment advice. Open the BIO and CIMO stock pages for the full models.
Not investment advice.